Baxter International Inc.

BAX Healthcare Medical Instruments & Supplies

Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024.

Revenue
+4.97%
EPS
+731.9%
Free cash flow
+255.6%
Total debt
−9.48%

Quarter to September 2026, against a year earlier

25.56 0.09 −0.35%
Market cap
$13.3B
P/E
0.0×
Fwd P/E
21.3×
Dividend yield
0.16%
F-score
4/9
Altman Z
2.12
Beneish M
−2.67
Dividend safety
0/100

Baxter International Inc. 10-Q filed Oct 29, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:31 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 30, 2026: 7 added · 3 removed · 61 modified; 19 with only figures updated; 6 moved without change

  1. Modified · ONGOING BUSINESS TRANSFORMATION

    We have incurred and expect to incur additional dis-synergies following our sale of our Kidney Care business due to the reduced size of our company and, as a result, we have undertaken certain restructuring actions (and intend to undertake additional actions) to help ensure our cost structuringstructure is appropriate to support our remaining business. See Note 10 of this Quarterly Report on Form 10-Q for additional information.